|
 |
|
|||||||
|
|||||||||
© 2001 by the American Diabetes Association, Inc.
Pharmacological Inhibition of Diabetic Retinopathy
Aminoguanidine and Aspirin
1 Departments of Medicine and Ophthalmology, and Center for Diabetes Research, Case Western Reserve University, Cleveland, Ohio
2 Department of Ophthalmology and Vision Research, University of Wisconsin, Madison, Wisconsin
Effects of aminoguanidine and aspirin on the development of retinopathy have been examined in 5-year studies of diabetic dogs. Either agent was administered daily in doses of 20–25 mg · kg-1 · day-1. Because severity of hyperglycemia greatly influences development of the retinopathy, special effort was devoted to maintaining comparable glycemia in experimental and control groups. The retinal vasculature was isolated by the trypsin digest method, and retinopathy was assessed by light microscopy. Diabetes for 5 years resulted, as expected, in saccular capillary aneurysms, pericyte ghosts, acellular capillaries, retinal hemorrhages, and other lesions. Administration of aminoguanidine essentially prevented the retinopathy, significantly inhibiting the development of retinal microaneurysms, acellular capillaries, and pericyte ghosts compared with diabetic controls. Aspirin significantly inhibited the development of retinal hemorrhages and acellular capillaries over the 5 years of study, but had less effect on other lesions. Although diabetes resulted in significantly increased levels of advanced glycation end products (AGEs) (namely, pentosidine in tail collagen and aorta, and Hb-AGE), aminoguanidine had no significant influence on these parameters of glycation. Nitration of a retinal protein was significantly increased in diabetes and inhibited by aminoguanidine. The biochemical mechanism by which aminoguanidine has inhibited retinopathy thus is not clear. Aminoguanidine (but not aspirin) inhibited a diabetes-induced defect in ulnar nerve conduction velocity, but neither agent was found to influence kidney structure or albumen excretion.
CiteULike 
Del.icio.us 
Digg 
Reddit 
Technorati What's this?
This article has been cited by other articles:
|
|
 |
|
  R. A. Gubitosi-Klug, R. Talahalli, Y. Du, J. L. Nadler, and T. S. Kern 5-Lipoxygenase, but Not 12/15-Lipoxygenase, Contributes to Degeneration of Retinal Capillaries in a Mouse Model of Diabetic Retinopathy Diabetes, May 1, 2008; 57(5): 1387 - 1393. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Kaji, T. Usui, S. Ishida, K. Yamashiro, T. C. B. Moore, J. Moore, Y. Yamamoto, H. Yamamoto, and A. P. Adamis Inhibition of Diabetic Leukostasis and Blood-Retinal Barrier Breakdown with a Soluble Form of a Receptor for Advanced Glycation End Products Invest. Ophthalmol. Vis. Sci., February 1, 2007; 48(2): 858 - 865. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Zheng, S. J. Howell, D. A. Hatala, K. Huang, and T. S. Kern Salicylate-Based Anti-Inflammatory Drugs Inhibit the Early Lesion of Diabetic Retinopathy Diabetes, February 1, 2007; 56(2): 337 - 345. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. S. Kern, C. M. Miller, Y. Du, L. Zheng, S. Mohr, S. L. Ball, M. Kim, J. A. Jamison, and D. P. Bingaman Topical Administration of Nepafenac Inhibits Diabetes-Induced Retinal Microvascular Disease and Underlying Abnormalities of Retinal Metabolism and Physiology Diabetes, February 1, 2007; 56(2): 373 - 379. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Zheng, B. Gong, D. A. Hatala, and T. S. Kern Retinal Ischemia and Reperfusion Causes Capillary Degeneration: Similarities to Diabetes Invest. Ophthalmol. Vis. Sci., January 1, 2007; 48(1): 361 - 367. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. C. Amrite, S. P. Ayalasomayajula, N. P. S. Cheruvu, and U. B. Kompella Single Periocular Injection of Celecoxib-PLGA Microparticles Inhibits Diabetes-Induced Elevations in Retinal PGE2, VEGF, and Vascular Leakage. Invest. Ophthalmol. Vis. Sci., March 1, 2006; 47(3): 1149 - 1160. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Sun, C. Gerhardinger, Z. Dagher, T. Hoehn, and M. Lorenzi Aspirin at Low-Intermediate Concentrations Protects Retinal Vessels in Experimental Diabetic Retinopathy Through Non-Platelet-Mediated Effects Diabetes, December 1, 2005; 54(12): 3418 - 3426. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Genuth, W. Sun, P. Cleary, D. R. Sell, W. Dahms, J. Malone, W. Sivitz, V. M. Monnier, and for the DCCT Skin Collagen Ancillary Study Group Glycation and Carboxymethyllysine Levels in Skin Collagen Predict the Risk of Future 10-Year Progression of Diabetic Retinopathy and Nephropathy in the Diabetes Control and Complications Trial and Epidemiology of Diabetes Interventions and Complications Participants With Type 1 Diabetes Diabetes, November 1, 2005; 54(11): 3103 - 3111. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. R. Barile, S. I. Pachydaki, S. R. Tari, S. E. Lee, C. M. Donmoyer, W. Ma, L. L. Rong, L. G. Buciarelli, T. Wendt, H. Horig, et al. The RAGE Axis in Early Diabetic Retinopathy Invest. Ophthalmol. Vis. Sci., August 1, 2005; 46(8): 2916 - 2924. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. A. Kowluru and S. Odenbach Role of Interleukin-1{beta} in the Development of Retinopathy in Rats: Effect of Antioxidants Invest. Ophthalmol. Vis. Sci., November 1, 2004; 45(11): 4161 - 4166. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Zheng, C. Szabo, and T. S. Kern Poly(ADP-Ribose) Polymerase Is Involved in the Development of Diabetic Retinopathy via Regulation of Nuclear Factor-{kappa}B Diabetes, November 1, 2004; 53(11): 2960 - 2967. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Du, V. P. Sarthy, and T. S. Kern Interaction between NO and COX pathways in retinal cells exposed to elevated glucose and retina of diabetic rats Am J Physiol Regulatory Integrative Comp Physiol, October 1, 2004; 287(4): R735 - R741. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R A Kowluru and S Odenbach Role of interleukin-1{beta} in the pathogenesis of diabetic retinopathy Br. J. Ophthalmol., October 1, 2004; 88(10): 1343 - 1347. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. N. Frank Diabetic Retinopathy N. Engl. J. Med., January 1, 2004; 350(1): 48 - 58. [Full Text] [PDF]
|
|
|
|
 |
|
 E. M Kohner Aspirin for diabetic retinopathy BMJ, November 8, 2003; 327(7423): 1060 - 1061. [Full Text] [PDF]
|
|
|
|
|
|
W. Chen, D. B. Jump, M. B. Grant, W. J. Esselman, and J. V. Busik Dyslipidemia, but Not Hyperglycemia, Induces Inflammatory Adhesion Molecules in Human Retinal Vascular Endothelial Cells Invest. Ophthalmol. Vis. Sci., November 1, 2003; 44(11): 5016 - 5022. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. C. B. Moore, J. E. Moore, Y. Kaji, N. Frizzell, T. Usui, V. Poulaki, I. L. Campbell, A. W. Stitt, T. A. Gardiner, D. B. Archer, et al. The Role of Advanced Glycation End Products in Retinal Microvascular Leukostasis Invest. Ophthalmol. Vis. Sci., October 1, 2003; 44(10): 4457 - 4464. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. A. Ciulla, A. G. Amador, and B. Zinman Diabetic Retinopathy and Diabetic Macular Edema: Pathophysiology, screening, and novel therapies Diabetes Care, September 1, 2003; 26(9): 2653 - 2664. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Odetti, C. Pesce, N. Traverso, S. Menini, E. P. Maineri, L. Cosso, S. Valentini, S. Patriarca, D. Cottalasso, U. M. Marinari, et al. Comparative Trial of N-Acetyl-Cysteine, Taurine, and Oxerutin on Skin and Kidney Damage in Long-Term Experimental Diabetes Diabetes, February 1, 2003; 52(2): 499 - 505. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Stitt, T. A. Gardiner, N. L. Anderson, P. Canning, N. Frizzell, N. Duffy, C. Boyle, A. S. Januszewski, M. Chachich, J. W. Baynes, et al. The AGE Inhibitor Pyridoxamine Inhibits Development of Retinopathy in Experimental Diabetes Diabetes, September 1, 2002; 51(9): 2826 - 2832. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A P Adamis Is diabetic retinopathy an inflammatory disease? Br. J. Ophthalmol., April 1, 2002; 86(4): 363 - 365. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Diabetes | Diabetes Care | Clinical Diabetes | Diabetes Spectrum |